Our success in 2011 gives us a strong position on which to build. In 2012, we will focus on the continued growth and leadership of our marketed products and the advancement of our strong pipeline.
Commercial Execution
Stabilized AVONEX market share
Introduced the AVONEX PEN to European markets and Canada
Hit key milestones important for unlocking the value of TYSABRI
JCV assay made commercially available in the US and EU
Product label updated in the EU and the US in 2012
Successful appeal of FAMPYRA in EU; launched in Germany with additional launches in 2012
Advance Late-Stage Pipeline
BG-12, oral MS candidate: potential launch 2013
Long-lasting factor VIII and factor IX program candidates for hemophilia: data readouts expected 2012
PEGylated interferon beta-1a for MS: phase III data expected 2013
Strengthen R&D/Early-stage Pipeline
Dexpramipexole in ALS: enrolled first phase III study; fastest enrollment in company history
Daclizumab-HYP: positive data readout from first registrational trial
Collaboration with Portola Pharmaceuticals to develop and commercialize an oral, highly selective Syk inhibitor
Collaboration in 2012 with Isis Pharmaceuticals for compound to target spinal muscular atrophy
Culture of Excellence
Focused strategic direction
Advanced in building a culture that attracts the best people
Better, crisper decision-making
Sense of accountability throughout the organization
Result: more nimble, focused and ambitious organization
